Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Open accessThe DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is characterized by a deficit in β-cell mass, impaired insulin secretion in response to various stimuli (1–3), as well as a variable extent of insulin resistance (4). More specifically, regarding β-cell function, a significant reduction of the incretin effect, i.e., the postprandial augmentation of insulin secretion by gut hormones, has been described in patients with type 2 diabetes (5). Thus, while the two incretin hormones gastric inhibitory polypeptide (glucose-dependent insulinotopic polypeptide [GIP]) and glucagon-like peptide 1 (GLP-1) are held responsible for ∼50–70% of the postprandial insulin responses in healthy individuals (6), their contribution to the overall insulin responses after oral glucose ingestion may amount to <20% in patients with type 2 diabetes (5,7). The reasons underlying the loss of incretin activity in type 2 diabetes are still incompletely understood. The present article reviews the available evidence regarding disturbances in the enteroinsular axis in patients with type 2 diabetes and provides possible explanations for their etiologies, focusing on the personal experience of the authors. ### Secretion of incretin hormones in patients with type 2 diabetes. Because the incretin effect has been related to the secretion and insulinotropic action of GIP and GLP-1 (8,9), it was obvious to compare these parameters between patients with type 2 diabetes and healthy control subjects: Regarding the secretion of GIP, elevated, normal, and reduced plasma levels have been described in patients with type 2 diabetes (10–15). However, taking together all the evidence available, the secretion of GIP appears to be relatively unchanged in type 2 diabetic patients. For GLP-1 release, the case is even more complex. Several studies have reported significant reductions in GLP-1 levels after mixed meal ingestion in patients with type 2 diabetes (10,16,17). In addition, one study has found minor impairments in GLP-1 levels in individuals with impaired glucose …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The current consensus in the literature is that GLP-1 and GIP circulation levels are comparable between T2D patients and nondiabetic controls in response to nutrient challenges.158”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“The diminished incretin effect in patients with type 2 diabetes was described more than 20 years ago (5), but even now the underlying causes remain elusive.”
BackgroundSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“By these means, the hyperglycemia in patients with type 2 diabetes can readily be normalized by the intravenous administration of GLP-1 (26), even at relatively low doses (27).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
The Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Islet Pathology and the Pathogenesis of Type 1 and Type 2 Diabetes mellitus Revisited
Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., & Heitz, P. U. (1985) · Pathology and Immunopathology Research · doi:10.1159/000156969 · Cited by 577
T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
BRUNZELL, J. D., ROBERTSON, R. P., LERNER, R. L., HAZZARD, W. R., ENSINCK, J. W., BIERMAN, E. L., & PORTE, D. (1976) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-42-2-222 · Cited by 505
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483
Miyawaki, K., Yamada, Y., Yano, H., Niwa, H., Ban, N., Ihara, Y., Kubota, A., Fujimoto, S., Kajikawa, M., Kuroe, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.26.14843 · Cited by 454
Gerich, J. E. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.4.0338 · Cited by 420
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Muscelli, E., Mari, A., Casolaro, A., Camastra, S., Seghieri, G., Gastaldelli, A., Holst, J. J., & Ferrannini, E. (2008) · Diabetes · doi:10.2337/db07-1315 · Cited by 409 · cited 2×
“induced GLP-1 concentrations in patients with long-standing type 2 diabetes and subjects with impaired glucose tolerance (10,16,17).”
BackgroundOrskov, C., Jeppesen, J., Madsbad, S., & Holst, J. J. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115012 · Cited by 378
Downregulation of GLP-1 and GIP Receptor Expression by Hyperglycemia
Xu, G., Kaneto, H., Laybutt, D. R., Duvivier-Kali, V. F., Trivedi, N., Suzuma, K., King, G. L., Weir, G. C., & Bonner-Weir, S. (2007) · Diabetes · doi:10.2337/db06-1033 · Cited by 377
Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369
Self-citationInsulin secretion in diabetes mellitus
Pfeifer, M. A., Halter, J. B., & Porte, D. (1981) · The American Journal of Medicine · doi:10.1016/0002-9343(81)90579-9 · Cited by 367
Vollmer, K., Holst, J. J., Baller, B., Ellrichmann, M., Nauck, M. A., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes · doi:10.2337/db07-1124 · Cited by 356
Self-citationReduced Incretin Effect in Type 2 Diabetes
Knop, F. K., Vilsbøll, T., Højberg, P. V., Larsen, S., Madsbad, S., Vølund, A., Holst, J. J., & Krarup, T. (2007) · Diabetes · doi:10.2337/db07-0100 · Cited by 349
Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia · doi:10.1007/s00125-003-1103-y · Cited by 314
Self-citationSchäfer, S. A., Tschritter, O., Machicao, F., Thamer, C., Stefan, N., Gallwitz, B., Holst, J. J., Dekker, J. M., t’Hart, L. M., Nijpels, G., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0753-6 · Cited by 308
Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1
Gromada, J., Holst, J. J., & Rorsman, P. (1998) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050558 · Cited by 258
Clinical Endocrinology and Metabolism
(2023) · Clinical Endocrinology and Metabolism · doi:10.31579/2834-8761/cem · Cited by 242
Vilsbøll, T., Knop, F. K., Krarup, T., Johansen, A., Madsbad, S., Larsen, S., Hansen, T., Pedersen, O., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030738 · Cited by 232
Meier, J. J., Hücking, K., Holst, J. J., Deacon, C. F., Schmiegel, W. H., & Nauck, M. A. (2001) · Diabetes · doi:10.2337/diabetes.50.11.2497 · Cited by 230
Self-citationLynn, F. C., Pamir, N., Ng, E. H. C., McIntosh, C. H. S., Kieffer, T. J., & Pederson, R. A. (2001) · Diabetes · doi:10.2337/diabetes.50.5.1004 · Cited by 208
Gromada, J., Bokvist, K., Ding, W.-G., Holst, J. J., Nielsen, J. H., & Rorsman, P. (1998) · Diabetes · doi:10.2337/diab.47.1.57 · Cited by 189
Ryskjær, J., Deacon, C. F., Carr, R. D., Krarup, T., Madsbad, S., Holst, J., & Vilsbøll, T. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02221 · Cited by 181
Gut hormones and diabetes mellitus
Creutzfeldt, W., & Nauck, M. (1992) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610080206 · Cited by 176
Self-citationGastric Inhibitory Polypeptide and Glucagon-Like Peptide-1 in the Pathogenesis of Type 2 Diabetes
Nauck, M. A., Baller, B., & Meier, J. J. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s190 · Cited by 163
Self-citationBeta-cell function improved by supplementing basal insulin secretion in mild diabetes.
Turner, R. C., McCarthy, S., Holman, R. R., & Harris, E. (1976) · BMJ · doi:10.1136/bmj.1.6020.1252 · Cited by 151
Pilgaard, K. A., Jensen, C. B., Schou, J. H., Lyssenko, V., Wegner, L., Brøns, C., Vilsbøll, T., Hansen, T. F., Madsbad, S., Holst, J. J., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1307-x · Cited by 147
Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 146
Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides · doi:10.1016/j.regpep.2004.06.020 · Cited by 137
Self-citationEnhanced secretion of glucagon-like peptide 1 by biguanide compounds
Yasuda, N., Inoue, T., Nagakura, T., Yamazaki, K., Kira, K., Saeki, T., & Tanaka, I. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02565-2 · Cited by 137
The pathogenesis of NIDDM involves a defective expression of the GIP receptor
Holst, J. J., Gromada, J., & Nauck, M. A. (1997) · Diabetologia · doi:10.1007/s001250050779 · Cited by 136
Self-citationHypersecretion of Gastric Inhibitory Polypeptide Following Oral Glucose in Diabetes Mellitus
Ross, S. A., Brown, J. C., & Dupré, J. (1977) · Diabetes · doi:10.2337/diab.26.6.525 · Cited by 135
Gromada, J., Ding, W.-G., Barg, S., Renström, E., & Rorsman, P. (1997) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s004240050431 · Cited by 110
Effects of beta-cell rest on beta-cell function: a review of clinical and preclinical data
Brown, R. J., & Rother, K. I. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00272.x · Cited by 104
Immunoreactive Gastric Inhibitory Polypeptide*
KRARUP, T. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-1-122 · Cited by 96
Influence of Gastric Inhibitory Polypeptide Antiserum on Glucose-Induced Insulin Secretion in Rats
EBERT, R., & CREUTZFELDT, W. (1982) · Endocrinology · doi:10.1210/endo-111-5-1601 · Cited by 93
Schäfer, S., Müssig, K., Staiger, H., Machicao, F. E., Stefan, N., Gallwitz, B., Häring, H.-U., & Fritsche, A. (2009) · Diabetologia · doi:10.1007/s00125-009-1344-5 · Cited by 92
Lynn, F. C., Thompson, S. A., Pospisilik, J. A., Ehses, J. A., Hinke, S. A., Pamir, N., McIntosh, C. H. S., & Pederson, R. A. (2003) · The FASEB Journal · doi:10.1096/fj.02-0243fje · Cited by 91
Gastric Inhibitory Polypeptide (GIP) in Maturity-onset Diabetes Mellitus
Crockett, S. E., Mazzaferri, E. L., & Cataland, S. (1976) · Diabetes · doi:10.2337/diab.25.10.931 · Cited by 91
Højberg, P. V., Zander, M., Vilsbøll, T., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetologia · doi:10.1007/s00125-008-0943-x · Cited by 89
Meier, J. J., Gallwitz, B., Askenas, M., Vollmer, K., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1863-7 · Cited by 87
Self-citationMeier, J. J., Gallwitz, B., Kask, B., Deacon, C. F., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2004) · Diabetes · doi:10.2337/diabetes.53.suppl_3.s220 · Cited by 85
Self-citationGlucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptide
Meier, J. J., & Nauck, M. A. (2004) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2004.08.007 · Cited by 82
Self-citationSafety and Efficacy of Normalizing Fasting Glucose With Bedtime NPH Insulin Alone in NIDDM
Cusi, K., Cunningham, G. R., & Comstock, J. P. (1995) · Diabetes Care · doi:10.2337/diacare.18.6.843 · Cited by 72
Almind, K., Ambye, L., Urhammer, S. A., Hansen, T. F., Echwald, S. M., Holst, J. J., Gromada, J., Thorens, B., & Pedersen, O. B. (1998) · Diabetologia · doi:10.1007/s001250051051 · Cited by 68
Kubota, A., Yamada, Y., HAYAMI, T., Yasuda, K., Someya, Y., Ihara, Y., Kagimoto, S., Watanabe, R., Taminato, T., Tsuda, K., et al. (1996) · Diabetes · doi:10.2337/diab.45.12.1701 · Cited by 62
Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2178 · Cited by 61
Self-citationHøjberg, P. V., Vilsbøll, T., Zander, M., Knop, F. K., Krarup, T., Vølund, A., Holst, J. J., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02579.x · Cited by 56
Tseng, C. C., Boylan, M. O., Jarboe, L. A., Usdin, T. B., & Wolfe, M. M. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.270.4.e661 · Cited by 56
Vollmer, K., Gardiwal, H., Menge, B. A., Goetze, O., Deacon, C. F., Schmidt, W. E., Holst, J. J., & Meier, J. J. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2197 · Cited by 51
Self-citationNauck, M. A., B�sing, M., �rskov, C., Siegel, E. G., Talartschik, J., Baartz, A., Baartz, T., Hopt, U. T., Becker, H. D., & Creutzfeldt, W. (1993) · Acta Diabetologica · doi:10.1007/bf00572873 · Cited by 50
Self-citationThe contribution of incretin hormones to the pathogenesis of type 2 diabetes
Meier, J. J. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.007 · Cited by 46
Self-citationMeier, J. J., Nauck, M. A., Siepmann, N., Greulich, M., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Gallwitz, B. (2003) · Metabolism · doi:10.1016/s0026-0495(03)00327-5 · Cited by 43
Self-citationIs secretion of glucagon-like peptide-1 reduced in type 2 diabetes mellitus?
Meier, J. J., & Nauck, M. A. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0946 · Cited by 41
Self-citationAmland, P. F., Jorde, R., Aanderud, S., Burhol, P. G., & Giercksky, K.-E. (1985) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528509091657 · Cited by 41
The potential role of glucagon-like peptide 1 in diabetes.
Meier, J. J., & Nauck, M. A. (2004) · PubMed · Cited by 39
Self-citationManagement of type 2 diabetes: the role of incretin mimetics
Stonehouse, A. H., Holcombe, J. H., & Kendall, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.15.2095 · Cited by 29
The enteroinsular axis may mediate the diabetogenic effects of TCF7L2 polymorphisms
Nauck, M. A., & Meier, J. J. (2007) · Diabetologia · doi:10.1007/s00125-007-0832-8 · Cited by 25
Self-citationJessen, L., & D’Alessio, D. A. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.10.013 · Cited by 7
Research works printed but not linked: 5
- Meier, 2005, Insulin secretion, 961
- Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (Abstract), Diabetologia, 19, 271
- Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes, Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
- Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
- Pfeifer, 1981, Insulin secretion in diabetes mellitus, Am J Med, 70, 579, 10.1016/0002-9343(81)90579-9 · DOI · Paper page
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Self-citationType 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Self-citationReed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Metadata
- Authors
- Meier, J. J., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 1117-1125
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857890
- OpenAlex
- W2097621088
- Cited by
- 215
- References
- 72
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 15 · 2018: 8 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 27 · 2012: 19
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, enteroinsular axis, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin secretion, postprandial insulin secretion, beta-cell mass, insulin resistance
- MeSH terms
- Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Models, Biological, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.